Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chiara Battisegola
Institution:
University of Naples Federico II
Observed institution:
University of Naples Federico II
ORCID:
0009-0000-5729-7237
Observed ORCID:
0009-0000-5729-7237
OpenAlex ID:
A5094013636
Opportunities and Challenges of Arginase Inhibitors in Cancer: A Medicinal Chemistry Perspective
2024
·
Mariacristina Failla
, Maria Cristina Molaro
, et al.
·
Journal of Medicinal Chemistry
·
30
Galactose: A Versatile Vector Unveiling the Potentials in Drug Delivery, Diagnostics, and Theranostics
2024
·
Chiara Battisegola
, Chiara Billi
, et al.
·
Pharmaceuticals
·
27
PDF
Synthesis of Arginase Inhibitors: An Overview
2025
·
Maria Cristina Molaro
, Chiara Battisegola
, et al.
·
Pharmaceutics
·
9
PDF
RETRACTED: FS536, a novel nitric oxide-releasing doxorubicin hybrid, reverts multidrug resistance in lung cancer cells
2025
·
Benedetta Romano
, Maria Cristina Molaro
, et al.
·
Journal of Controlled Release
·
3
Retraction notice to “FS536, a novel nitric oxide-releasing doxorubicin hybrid, reverts multidrug resistance in lung cancer cells” [Journal of Controlled Release 382 (2025) 113732]
2026
·
Benedetta Romano
, Maria Cristina Molaro
, et al.
·
Journal of Controlled Release
Synthetic protocols for first- and second-generation arginase inhibitors
2026
·
Federica Sodano
, Marica Erminia Schiano
, et al.
·
Methods in enzymology on CD-ROM/Methods in enzymology
Synthetic protocols for third- and fourth-generation arginase inhibitors
2026
·
Federica Sodano
, Marica Erminia Schiano
, et al.
·
Methods in enzymology on CD-ROM/Methods in enzymology
Show more works
View as search
Works count:
7
Citation count:
69
H-index:
3
I10-index:
2
Year
Topic
Type